Prospective Randomized Trial of Esomeprazole versus Lansoprazole and Omeprazole Based Triple Therapy for H. Pylori Eradication in an Iranian Populatio

Phase 2

• Conditions: peptic ulcer-gastritis-non ulcer dyspepsia.; Gastric ulcer-Duodenal ulcer-Gastritis, unspecified-Dyspepsia; k25-k26-k2

• Registration Number: IRCT201204043836N4
• Lead Sponsor: Jundishapour Ahvaz Uuniversity of Medical Science

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 February 2018

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 300

Inclusion Criteria

Patients with endoscopic evidence of peptic ulcer, non-ulcer dyspepsia, gastritis or acid reflux with confirmation H. Pylori, either by histology or a positive Urease test will enroll in the study.
Exclusion criteria: previous treatment of H. Pylori infection; previous use of any antibiotics or bismuth subcitrate or any PPI or H2 blocker within four weeks prior to endoscopy; use of NSAIDs for more than four weeks; history of allergy to medications; previous history of any gastric surgery; underlying diseases such as cirrhosis or, uremia and pregnancy

Exclusion Criteria

Not provided

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Eradication helicobacter pylori. Timepoint: 4 weeks. Method of measurement: Urea breath test.

Secondary Outcome Measures

Name	Time	Method
Side effects will systematically record throughout the study and will assess using a checklist administered by a physician. Timepoint: During study. Method of measurement: 1-None or only mild: mild discomfort which dont interfere with the patients’ normal daily activities. 2-Intermediate: discomfort or side effects which interfered with the patients’ normal daily activities. 3-Severe: side effects requiring cessation of treatment.